Delin Ventures
Delin is an early-stage fund focused on investments and company-building with remarkable entrepreneurs and scientists in two sectors: life sciences, and the future of work and learning.
Life Sciences
Within Life Sciences, we are focused on the cellular immunotherapy space. Firstly, we invest in the development of innovative therapeutic concepts, and secondly in the infrastructure supporting the successful R&D of novel cellular immunotherapies. This includes the manufacturing and delivery, which is still a major technical, logistical, and regulatory bottleneck. In particular, Delin is supporting technologies to transform flexible manufacturing of cellular immunotherapies to deliver life-saving treatments to patients where they are needed.
Our initial ticket size is up to £5M at the seed stage, with a maximum lifetime investment of up to £18M. Typically Delin aims to lead seed-stage investments, and participate up to and including Series A.
Future of Work & Learning
Within the Future of Work & Learning, we are investing in European technology startups that unlock human potential.
We lead Pre-Seed and Seed rounds with up to £2m. We’re focused on B2B cases shaping how we’ll work and learn.
We are particularly interested in solutions in the areas of Productivity, HR Tech, New Work, Workforce Upskilling, Simulations, and the Frontline Space.
Once we invest, we aim to be a partner with the company on developing and refining companies’ development plans, supporting their teams to create value and mitigate risk, scale-up successfully, and enabling them to access essential advisor networks and partnerships.